DE60328182D1 - Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase - Google Patents

Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase

Info

Publication number
DE60328182D1
DE60328182D1 DE60328182T DE60328182T DE60328182D1 DE 60328182 D1 DE60328182 D1 DE 60328182D1 DE 60328182 T DE60328182 T DE 60328182T DE 60328182 T DE60328182 T DE 60328182T DE 60328182 D1 DE60328182 D1 DE 60328182D1
Authority
DE
Germany
Prior art keywords
sulfamides
inhibition
heteroaryl substituted
gamma secretase
substituted spirocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60328182T
Other languages
English (en)
Inventor
Ian James Collins
Laura Catherine Cooper
Timothy Harrison
Linda Elizabeth Keown
Andrew Madin
Mark Peter Ridgill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0209996A external-priority patent/GB0209996D0/en
Priority claimed from GB0223873A external-priority patent/GB0223873D0/en
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of DE60328182D1 publication Critical patent/DE60328182D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
DE60328182T 2002-05-01 2003-04-24 Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase Expired - Lifetime DE60328182D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0209996A GB0209996D0 (en) 2002-05-01 2002-05-01 Therapeutic agents
GB0223873A GB0223873D0 (en) 2002-10-14 2002-10-14 Therapeutic agents
US42460802P 2002-11-07 2002-11-07
PCT/GB2003/001763 WO2003093252A1 (en) 2002-05-01 2003-04-24 Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase

Publications (1)

Publication Number Publication Date
DE60328182D1 true DE60328182D1 (de) 2009-08-13

Family

ID=29407321

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60328182T Expired - Lifetime DE60328182D1 (de) 2002-05-01 2003-04-24 Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase

Country Status (7)

Country Link
US (3) US7041689B2 (de)
EP (1) EP1503998B1 (de)
AT (1) ATE435219T1 (de)
AU (1) AU2003229932B2 (de)
CA (1) CA2484159C (de)
DE (1) DE60328182D1 (de)
WO (1) WO2003093252A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2427206C (en) * 2000-11-02 2011-06-28 Merck Sharp & Dohme Limited Sulfamides as gamma-secretase inhibitors
KR100927304B1 (ko) 2001-12-27 2009-11-18 다이이찌 세이야꾸 가부시기가이샤 β-아밀로이드 단백 생산·분비 저해제
WO2003093252A1 (en) * 2002-05-01 2003-11-13 Merck Sharp & Dohme Limited Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase
GB0209995D0 (en) * 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0225475D0 (en) * 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
GB0308318D0 (en) 2003-04-10 2003-05-14 Merck Sharp & Dohme Therapeutic agents
KR20060066057A (ko) 2003-06-30 2006-06-15 다이이찌 세이야꾸 가부시기가이샤 복소환 메틸 설폰 유도체
CA2539042A1 (en) * 2003-09-24 2005-04-07 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
US8242103B2 (en) 2005-05-19 2012-08-14 Merck Sharp & Dohme Limited Sulphamides for treatment of cancer
EP1996182A4 (de) 2006-02-27 2009-08-12 Univ Johns Hopkins Krebsbehandlung mit gamma-sekretasehemmern
WO2008076556A2 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
EP2121633A2 (de) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazinderivate zur behandlung von alzheimer-krankheit und verwandten leiden
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2307381B1 (de) 2008-06-09 2021-01-13 Ludwig-Maximilians-Universität München Neue arzneimittel zur inhibierung der aggregation von proteinen, die an mit der proteinaggregation in zusammenhang stehenden krankheiten und/oder neurodegenertiven krankheiten beteiligt sind
CA2743436C (en) 2008-11-24 2017-10-31 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
TWI519530B (zh) 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶(calpain)抑制劑之用途
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
JP2013514287A (ja) * 2009-12-17 2013-04-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング スフィンゴシンキナーゼの阻害薬
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (de) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Kondensierte pyrazolderivate als neue erk-hemmer
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
AU2013312358B2 (en) 2012-09-07 2018-08-09 Massachusetts Eye & Ear Infirmary Treating hearing loss
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
AU2017212655B2 (en) 2016-01-29 2024-01-18 Decibel Therapeutics, Inc. Expansion and differentiation of inner ear supporting cells and methods of use thereof
WO2017200762A2 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
JP6904612B2 (ja) 2016-12-16 2021-07-21 パイプライン セラピューティクス, インコーポレイテッド 蝸牛シナプス障害を処置する方法
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3833668A4 (de) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Prmt5-inhibitoren
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
AU2020408148A1 (en) 2019-12-17 2022-06-16 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2024049931A1 (en) 2022-09-02 2024-03-07 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3406184A (en) * 1966-05-04 1968-10-15 Du Pont Addition compounds of norbornadienes and quadricyclenes with bis(trifluoromethyl) thioketene and their s-oxides and s-dioxides
US3715362A (en) * 1970-08-17 1973-02-06 Lilly Co Eli Tetracyclic aziridine and method for its preparation
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
CA2276278C (en) 1997-02-27 2009-04-07 Takeda Chemical Industries, Ltd. Amine compounds, their production and use
JP2003528076A (ja) * 2000-03-20 2003-09-24 メルク シャープ エンド ドーム リミテッド スルホンアミド置換架橋ビシクロアルキル誘導体
CA2427206C (en) 2000-11-02 2011-06-28 Merck Sharp & Dohme Limited Sulfamides as gamma-secretase inhibitors
WO2003093252A1 (en) * 2002-05-01 2003-11-13 Merck Sharp & Dohme Limited Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase
GB0209997D0 (en) * 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0209991D0 (en) * 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
US20050182109A1 (en) 2005-08-18
AU2003229932B2 (en) 2008-12-11
CA2484159A1 (en) 2003-11-13
ATE435219T1 (de) 2009-07-15
EP1503998A1 (de) 2005-02-09
US7041689B2 (en) 2006-05-09
AU2003229932A1 (en) 2003-11-17
US7282513B2 (en) 2007-10-16
WO2003093252A1 (en) 2003-11-13
EP1503998B1 (de) 2009-07-01
US20060173054A1 (en) 2006-08-03
CA2484159C (en) 2011-02-22
US20080070895A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
DE60328182D1 (de) Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
ATE444293T1 (de) Cyclische sulfamide zur inhibierung von gamma- sekretase
ATE368031T1 (de) Neue gamma secretase inhibitoren
DE60112957D1 (de) Sulfamide als gamma-secretase-inhibitoren
DE60335731D1 (de) Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmer
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
TW200510405A (en) Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
ATE299890T1 (de) Inhibitoren von gamma-secretase
MXPA04001016A (es) Derivados de sulfonamida como inhibidores de la gamma secretasa.
NO20070606L (no) Inhibitorer av IAP
DE60317198D1 (de) Proteinkinaseinhibitoren
ATE457025T1 (de) Kinaseinhibitoren
NO20083684L (no) Laktam-inneholdende forbindelser og derivater derav som faktor XA-inhibitorer
DE60314639D1 (de) Fusionierte heteroaryl-derivative zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis
BR0014470A (pt) Inibidores de fab i
DE602006016313D1 (de) Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
DE50301261D1 (de) Phenylalaninderivate als herbizide
MX2008002234A (es) Inhibidores de sulfonamida n-biciclico puenteados de gamma secretasa.
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
DE60233884D1 (de) 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-derivate als pde-4-hemmer zur behandlung von neurologischen syndromen
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
ATE502631T1 (de) Verbindungen zur behandlung von stoffwechselstörungen
DE60230652D1 (de) Arylsulfanyl und heteroarylsulfanyl-derivate zur behandlung von schmerz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition